Related Experiment Video
Updated: May 18, 2026
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent
Barbara A Jereczek-Fossa1, Gaia Piperno, Sara Ronchi
1Departments of *Radiotherapy §Medical Physics #Urology, European Institute of Oncology ∥CNAO Foundation, National Center for Oncological Hadrontherapy †University of Milan ¶Department of Bioengineering, Politecnico di Milano, Milan ‡Division of Radiotherapy, IRCCS Multimedia. Sesto S. Giovanni and Multimedica Holding, Castellanza, Italy.
Objectives:
To evaluate stereotactic body radiotherapy (SBRT) for single abdominal lymph node cancer recurrence.
Methods:
Inclusion criteria for this retrospective study were as follows: adult oligometastatic cancer patients with single abdominal lymph node recurrence that underwent SBRT but not other local therapy, written informed consent for treatment. Previous radiotherapy or concomitant systemic therapy were allowed. Toxicity and tumor response were evaluated using Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer Scale and Response Evaluation Criteria in Solid Tumors.
Results:
Sixty-nine patients (94 lesions) underwent SBRT (median 24 Gy/3 fractions). Primary diagnosis included urological, gastrointestinal, gynecologic, and other malignancies. Concomitant systemic therapy was performed in 35 cases. Median follow-up was 20 months. Two grade 3 acute and 1 grade 4 late toxicity events were registered. Complete radiologic response, partial response, stabilization, and progressive disease were observed in 36 (44%), 21 (26%), 20 (25%), and 4 (5%) lesions, respectively, out of 81 evaluable lesions. Response rates were similar when analysis was restricted to lesions treated with exclusive SBRT (no concomitant therapy). Actuarial 3-year in-field progression-free interval, progression-free survival and overall-survival rates were 64.3%, 11.7%, and 49.9%, respectively. Overall-survival rates were significantly higher in favorable histology cases (prostate and kidney tumors). Pattern of failure was predominantly out-field.
Conclusions:
SBRT is a feasible approach for single abdominal lymph node recurrence, offering excellent in-field tumor control with low-toxicity profile. Future studies are warranted to identify the patients that benefit most from this treatment. The optimal combination with systemic treatment should also be defined.
